ATE519495T1 - Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe - Google Patents

Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe

Info

Publication number
ATE519495T1
ATE519495T1 AT09075024T AT09075024T ATE519495T1 AT E519495 T1 ATE519495 T1 AT E519495T1 AT 09075024 T AT09075024 T AT 09075024T AT 09075024 T AT09075024 T AT 09075024T AT E519495 T1 ATE519495 T1 AT E519495T1
Authority
AT
Austria
Prior art keywords
receptor agonist
therapeutic procedures
selective receptor
selective
receptors
Prior art date
Application number
AT09075024T
Other languages
English (en)
Inventor
Thue Schwartz
Original Assignee
7Tm Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0503110A external-priority patent/GB0503110D0/en
Application filed by 7Tm Pharma As filed Critical 7Tm Pharma As
Application granted granted Critical
Publication of ATE519495T1 publication Critical patent/ATE519495T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
AT09075024T 2004-03-17 2005-03-17 Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe ATE519495T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200400436 2004-03-17
US55893204P 2004-04-01 2004-04-01
US58596404P 2004-07-06 2004-07-06
GB0503110A GB0503110D0 (de) 2005-02-14 2005-02-14

Publications (1)

Publication Number Publication Date
ATE519495T1 true ATE519495T1 (de) 2011-08-15

Family

ID=43302286

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09075024T ATE519495T1 (de) 2004-03-17 2005-03-17 Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe
AT05716258T ATE490779T1 (de) 2004-03-17 2005-03-17 Y4-selektive rezeptoragonist für therapeutische interventionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05716258T ATE490779T1 (de) 2004-03-17 2005-03-17 Y4-selektive rezeptoragonist für therapeutische interventionen

Country Status (15)

Country Link
US (1) US20080269114A1 (de)
EP (3) EP2060266B1 (de)
JP (1) JP2007529463A (de)
AT (2) ATE519495T1 (de)
AU (1) AU2005224028B2 (de)
BR (1) BRPI0508935A (de)
CA (1) CA2560174A1 (de)
DE (1) DE602005025199D1 (de)
DK (1) DK2060266T3 (de)
EA (1) EA012071B1 (de)
GB (1) GB2427551B (de)
IL (1) IL177681A0 (de)
MX (1) MXPA06010345A (de)
PL (1) PL2060266T3 (de)
WO (1) WO2005089786A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361967A (zh) * 2004-03-17 2009-02-11 7Tm制药联合股份有限公司 用于治疗性干预的y2/y4选择性受体激动剂
CA2560166A1 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
WO2006091505A2 (en) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
US8466104B2 (en) * 2005-08-26 2013-06-18 Abbvie Inc. Therapeutically active alpha MSH analogues
EP1934254A1 (de) * 2005-09-21 2008-06-25 7TM Pharma A/S Selektive y4 rezeptor agonisten für therapeutische eingriffe
BRPI0520566A2 (pt) * 2005-09-21 2009-05-19 7Tm Pharma As agonistas de receptores y2 seletivos para intervenções terapêuticas
JPWO2007100071A1 (ja) * 2006-02-24 2009-07-23 萬有製薬株式会社 腸管の機能異常を伴う疾患の治療剤としてのｎｐｙｙ４アゴニスト
PE20090213A1 (es) 2007-05-04 2009-02-28 Bristol Myers Squibb Co Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
WO2008137435A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
JP2010533157A (ja) * 2007-07-09 2010-10-21 インペリアル イノベーションズ リミテッド ヒト膵臓ポリペプチド（ｈｐｐ）類似体および摂食行動に対するそれらの影響
EA018709B1 (ru) 2007-07-17 2013-10-30 Бристол-Маерс Сквибб Компани Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
RU2504550C2 (ru) * 2008-05-16 2014-01-20 Ново Нордиск А/С Длительно действующие агонисты рецепторов y2 и(или) y4
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
GB0817067D0 (en) * 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
CN102438599B (zh) * 2009-03-04 2015-01-21 迈雅营养品有限公司 通过降低血糖水平来控制糖尿病的营养组合物和方法
GB201001333D0 (en) 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
MX2012011460A (es) 2010-04-08 2012-11-23 Squibb Bristol Myers Co Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
EA201270778A1 (ru) 2010-05-06 2013-04-30 Бристол-Майерс Сквибб Компани Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
EP2827885B1 (de) 2012-03-22 2018-08-15 Novo Nordisk A/S Zusammensetzungen von glp-1-peptiden und ihre herstellung
EP2850073B1 (de) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridon-analoga als gpr119-modulatoren
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
AU2014350197B2 (en) 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
EP3068795B1 (de) 2013-11-15 2019-03-06 Novo Nordisk A/S Beta-homoarginin substitution an position 35 von hpyy(1-36)
AU2016275735B2 (en) 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof
WO2018017910A1 (en) 2016-07-22 2018-01-25 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
EP4299118A3 (de) 2018-02-02 2024-04-10 Novo Nordisk A/S Feste zusammensetzungen mit einem glp-1-agonisten, einem salz aus n-(8-(2-hydroxybenzoyl)amino)caprylsäure und einem schmierstoff
GB202213305D0 (en) * 2022-09-12 2022-10-26 Univ Ulster Compositions for use in the treatment of diabetes or obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
CA2215694A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
CA2510199A1 (en) * 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US8603969B2 (en) * 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
GB0817067D0 (en) * 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment

Also Published As

Publication number Publication date
PL2060266T3 (pl) 2012-01-31
EP1729792B1 (de) 2010-12-08
EA200601720A1 (ru) 2007-04-27
AU2005224028A1 (en) 2005-09-29
GB2427551B (en) 2007-05-30
CA2560174A1 (en) 2005-09-29
EP2060266A1 (de) 2009-05-20
GB2427551A (en) 2007-01-03
BRPI0508935A (pt) 2007-09-25
US20080269114A1 (en) 2008-10-30
EP2060266B1 (de) 2011-08-10
EP2057996A2 (de) 2009-05-13
MXPA06010345A (es) 2007-06-19
EP2057996A3 (de) 2009-11-04
JP2007529463A (ja) 2007-10-25
DK2060266T3 (da) 2011-11-14
AU2005224028B2 (en) 2011-05-26
IL177681A0 (en) 2006-12-31
EA012071B1 (ru) 2009-08-28
WO2005089786A2 (en) 2005-09-29
WO2005089786A3 (en) 2006-06-15
ATE490779T1 (de) 2010-12-15
DE602005025199D1 (en) 2011-01-20
EP1729792A2 (de) 2006-12-13
GB0618824D0 (en) 2006-11-01

Similar Documents

Publication Publication Date Title
ATE519495T1 (de) Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe
DK1734971T3 (da) Indretning på polymerbasis med forsinket frigivelse
DE60317677D1 (de) Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
CL2008003847A1 (es) Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
ATE490239T1 (de) Substituierte phenylpiperidinderivate als melanocortin-4-rezeptormodulatoren
ATE474577T1 (de) Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten
DK2119715T3 (da) Benzimidazolderivat og dets anvendelse som AII-receptorantagonisk
DK2176250T3 (da) Substituerede heteroarylpiperidinderivater som modulatorer af melanocortin-4-receptorer
DE602005015577D1 (de) Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
GEP20094844B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors
CL2007000396A1 (es) Compuestos derivados de benzoil-piperidina, moduladores del receptor 5ht2/d3; composicion farmaceutica que los comprende;y su uso en el tratamiento y/o prevencion de patologias delsnc, tales como psicosis, esquizofrenia, depresion, ansiedad,adiccion a drogas y problemas cognitivos.
EA200800875A1 (ru) Рецепторные агонисты, селективные к y2 рецептору, для терапевтического воздействия
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
MXPA06010347A (es) Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
DK2059508T3 (da) 5,6-bisaryl-2-pyridin-carboxamidderivater, fremstilling deraf og terapeutisk anvendelse deraf som urotensin II-receptorantagonister
GEP20094843B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors
IL174693A0 (en) 3-(4-Aminophenyl)thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
DK1778239T3 (da) Adenosin-a3-receptor-agonister til behandling af sygdomme forbundet medtørre øjne, herunder sjögrens syndrom
ATE519498T1 (de) Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen
EP1751175A4 (de) Antagonisten des interleukin-1-rezeptors, zusammensetzungen und behandlungsverfahren
NO20062088L (no) Farmasoytisk preparat som omfatter en selektiv I1-imidazolinreseptoragonist og en angiotensin II-reseptorblokker
MX2007003545A (es) Composiciones y metodos para tratar trastornos cognitivos.
DE602005005476D1 (de) Selektive peptidische agonisten des vpac2-rezeptors
MX2010005590A (es) Composicion para el cuidado personal.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties